Literature DB >> 1864280

Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.

I Nilsson-Ehle1, M Hutchison, S J Haworth, S R Norrby.   

Abstract

Imipenem combined with cilastatin and meropenem was given as intravenous infusions of 1 g to eight young, healthy males on two separate occasions. Blood and urine samples were collected for up to 12 h. The terminal half-lives in plasma were 0.98 h and 1.11 h for meropenem and imipenem, respectively. The volume of distribution was smaller for meropenem than for imipenem (12.5 l and 14.4 l, respectively). The plasma clearance for meropenem was 188 (SD 31) ml/min and for imipenem 183 (SD 25) ml/min. Renal clearance was on average 139 (SD 24) ml/min and 135 (SD 11) ml/min, respectively. About 75% of the administered dose of both compounds was eliminated unchanged in urine. Non-renal clearance accounted for approximately 25% of the total clearance for both drugs. The kinetics of meropenem are very similar to those of imipenem given with cilastatin, and meropenem is as stable against renal metabolic degradation as imipenem combined with cilastatin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864280     DOI: 10.1007/bf01964413

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  Susceptibility of anaerobic bacteria to meropenem.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

2.  Safety evaluation of meropenem in animals: studies on the kidney.

Authors:  J C Topham; L B Murgatroyd; D V Jones; U R Goonetilleke; J Wright
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

3.  Activity of meropenem, against gram-positive bacteria.

Authors:  F H Kayser; G Morenzoni; A Strässle; K Hadorn
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

4.  In-vitro studies of meropenem.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

5.  The pharmacokinetics of meropenem in volunteers.

Authors:  R P Bax; W Bastain; A Featherstone; D M Wilkinson; M Hutchison; S J Haworth
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

6.  The disposition and metabolism of meropenem in laboratory animals and man.

Authors:  M P Harrison; S R Moss; A Featherstone; A G Fowkes; A M Sanders; D E Case
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

7.  Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate.

Authors:  E Krutzén; S E Bäck; I Nilsson-Ehle; P Nilsson-Ehle
Journal:  J Lab Clin Med       Date:  1984-12

8.  Imipenem/cilastatin: rationale for a fixed combination.

Authors:  S R Norrby
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug
  8 in total
  29 in total

1.  Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains.

Authors:  A Novelli; S Fallani; M I Cassetta; S Conti; T Mazzei
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

Review 2.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

3.  Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.

Authors:  B A Christensson; I Nilsson-Ehle; M Hutchison; S J Haworth; B Oqvist; S R Norrby
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 4.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

5.  Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients.

Authors:  C A Jaspers; H Kieft; B Speelberg; A Buiting; M van Marwijk Kooij; G J Ruys; H H Vincent; M C Vermeulen; A G Olink; I M Hoepelman
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 6.  Antibiotic dosing in critically ill patients with acute kidney injury.

Authors:  Rachel F Eyler; Bruce A Mueller
Journal:  Nat Rev Nephrol       Date:  2011-02-22       Impact factor: 28.314

7.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.

Authors:  G G Zhanel; A E Simor; L Vercaigne; L Mandell
Journal:  Can J Infect Dis       Date:  1998-07

8.  Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery.

Authors:  K Kanellakopoulou; H Giamarellou; P Papadothomakos; H Tsipras; J Chloroyiannis; R Theakou; P Sfikakis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

Review 9.  Meropenem clinical pharmacokinetics.

Authors:  J W Mouton; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 10.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.